Olanzapine

From Pubdrug

Jump to: navigation, search

This drug has a Black Box warning from the U.S. Food and Drug Administration.

Contents
image:pdred.GIF This page is not completed and has not been reviewed for accuracy.
You are reading a non-certified PubDrug document. This document is incomplete and not ready for final editing, review, and certification. Until this document is certified, any registered PubDrug user may edit its content.

Authored by: author signature (type four tildes)
Certified by: certifier signature (type four tildes)

Olanzapine quick reference

Olanzapine
Olanzapine general drug information
 Pronunciation oh-LAN-zuh-peen (.wav file)
 Trade Name(s) Zyprexa, Zyprexa Zydis, Symbyax
 How Supplied Tablets: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg
Orally disintegrating tablets: 5mg, 10mg, 15mg, 20mg
Powder for injection: 10mg per vial
Capsules (in combination with fluoxetine): 6mg/25mg, 6mg/50mg, 12mg/25mg, 12mg/50mg
 Generic Availability No generics available
 Patent Expiry Date 4/23/2011
 Classification thienobenzodiazepine
 Schedule Rx
 Pregnancy Category C
 Breast-feeding Do not breastfeed
Olanzapine chemical information
 IUPAC Name 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
 Empirical Formula C17H20N4S
 Molecular Weight 312.439 g/mol
pharmacokinetic information  |  [enter genomics URL (SEE www.pharmgkb.org) pharmacogenomic information]
[edit]

Description

In two to four sentences, describe the drug, how it works, and what it is used for.

[edit]

Mechanism of Action

Briefly describe the mechanism of action. If unknown, state the mechanism is unknown.

[edit]

Time Required for Therapeutic Response

  • Initial: type initial response time
  • Maximum: type maximum response time
[edit]

Pharmacokinetics

Absorption
Describe absorption characteristics of the drug.

Distribution
Describe distribution characteristics of the drug.

Metabolism
Describe metabolism characteristics of the drug.

Excretion
Describe excretion characteristics of the drug.

Back to top
[edit]

Special Population Pharmacokinetics

  • Renal insufficiency: Type renal insufficiency PK.
  • Hepatic insufficiency: Type hepatic insufficiency PK.
  • Hemodialysis: Type hemodialysis PK.
  • Geriatric: Type geriatric PK.
  • Pediatric: Type pediatric PK.
  • Gender: Type gender difference PK.
[edit]

Indications and Dosages

[edit]

FDA Approved Indications

Put FDA-approved indications in bold

  • Starting dose:
    • and put starting dose below
    • using bullet points
  • Maintenance dose:
    • put maintenance dosing below
    • using bullet points
  • Titration schedule: if any, type here (how to titrate the drug up or down), if not, erase the bullet point.

Add as many indications as necessary

  • Starting dose:
    • and put starting dose below
    • using bullet points
  • Maintenance dose:
    • put maintenance dosing below
    • using bullet points
  • Titration schedule: if any, type here (how to titrate the drug up or down), if not, erase the bullet point.
[edit]

Non-FDA Approved Indications

  • Put non-FDA-approved indications here. Use a bullet point for each indication. Dosing for these indications is unnecessary.
[edit]

Dosage Adjustment

Renal insufficiency: type renal insufficiency dosage adjustment here - use bullet points if necessary.
Hepatic insufficiency: type hepatic insufficiency dosage adjustment here.
Hemodialysis: type hemodialysis dosage adjustment here.
Geriatric: type geriatric dosage adjustment here.
Pediatric: type pedatric dosage adjustment here.
Gender: type gender dosage adjustment here.

[edit]

Dosage Limits

  • Adults: enter adult dosing limit
  • Elderly: enter elderly dosing limit
  • Adolescents and children: enter adolescent/children dosing limit (may be different, especially for small children and neonates...use extra bullet points for these special populations if necessary


Back to top
[edit]

Administration

  • Route: type route of administration (e.g. oral, rectal, vaginal, etc.)
  • Method:
    • Describe how it is to be taken for this route
    • Add extra bullet points if necessary
  • Route: if you have more than one route use more bullet points
  • Method:
    • Keep the same format throughout!
[edit]

Monitoring Parameters

  • Enter monitoring parameters using bullet points.
  • Use as many as you need.
[edit]

Contraindications/Precautions

[edit]

Black box warning

Explain black box warning in paragraph form.

[edit]

Contraindications

  • Enter contraindications using bullet points. Make sure this text is bold.
  • Another contraindication
[edit]

Precautions

  • Enter precautions using bullet points
  • Another precaution
[edit]

Pregnancy indications

Category ENTER PREGNANCY CATEGORY LETTER

Type a brief explanation of the pregnancy category.

[edit]

Breast-feeding indications

Type a brief explanation of the breastfeeding indications.

Back to top


[edit]

Drug-Drug, -Food, -Herb Interactions

Click the link above to go to the drug interactions page.

[edit]

Adverse Reactions/Side Effects

Olanzapine Adverse Reactions Chart
Incidence Body System Adverse Reactions
>10% All Somnolence (29%), Insomnia (12%), Dizziness (11%)
1-10% CNS Abnormal gait (6%), tremor (4%), akathisia (3%), hypertonia (3%), articulation impairment (2%)
Cardiovascular Postural hypotension (3%), tachycardia (3%), hypertension (2%)
Dermatologic Sweating
GI Dry mouth (9%), constipation (9%), dyspepsia (7%), vomiting (4%), increased appetite (3%)
Genitourinary Urinary incontinence (2%), urinary tract infection (2%)
Neuromuscular/skeletal Extremity pain (5%), joint pain (5%)
Respiratory Rhinitis (7%), increased cough (6%), pharyngitis (4%)
Miscellaneous Asthenia (10%), fever (6%), back pain (5%), amblyopia (3%), chest pain (3%)
<1% All ENTER ALL ADVERSE REACTIONS WITH AN INCIDENCE OF <1% HERE (just a list is sufficient)
[edit]

Overdosage Measures

Brief description of overdose, including how it may manifest.
Treatment:

  • Enter treatment using bullet points.
  • Add additional bullet points if needed.
Back to top
[edit]

Product Information and Distribution

Note: appearance only available for brand-name product
Dose/form Drug color(s) Drug shape Markings or odor/flavor
2.5 mg tablet white round Lilly 4112
5 mg tablet white round Lilly 4115
7.5 mg tablet white round Lilly 4116
10 mg tablet white round Lilly 4117
15 mg tablet blue oval Lilly 4415
20 mg tablet pink oval Lilly 4420
5 mg ODT yellow round 5
10 mg ODT yellow round 10
15 mg ODT yellow round 15
20 mg ODT yellow round 20
Powder for injection yellow - -
6 mg / 25 mg capsule yellow two-tone oval Lilly 3231 / 6/25
12 mg / 25 mg capsule red / yellow oval Lilly 3232 / 12/25
6 mg / 50 mg capsule white / yellow oval Lilly 3233 / 6/50
12 mg / 50 mg capsule red / white oval Lilly 3234 / 12/50
  • Inactive ingredients for tablets: carnuba wax, crospovidone, hydroxypropyl cellulose, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, titanium dioxide, FD&C Blue #2
  • Inactive ingredients for orally disintegrating tablets: parabens, aspartame, gelatin, mannitol
  • Inactive ingredients for powder for injection: hydrochloric acid, lactose, sodium hydrozide, tartaric acid
  • Inactive ingredients for capsules: black iron oxide, dimethicone, edible black ink, gelatin, pregelatinized starch, red iron oxide, sodium lauryl sulfate, titanium dioxide, yellow iron oxide
[edit]

Patient Information

  • Type patient information using bullet points.
  • Use as many bullet points as you need.
Back to top
[edit]

References

    [edit]

    PUBMED References

    [edit]

    Efficacy Trial Articles

    1. type links to articles - use PUBMED links to abstracts
    2. add as many as needed
    Back to top
    [edit]

    Therapeutic Class Comparison Articles

    1. type links to articles - use PUBMED links to abstracts
    2. add as many as needed
    [edit]

    Pharmacokinetics Articles

    1. type links to articles - use PUBMED links to abstracts
    2. add as many as needed
    Back to top
    [edit]

    Drug Interaction Articles

    1. type links to articles - use PUBMED links to abstracts
    2. add as many as needed
    [edit]

    Adverse Effects Articles

    1. type links to articles - use PUBMED links to abstracts
    2. add as many as needed
    Back to top
    [edit]

    Compliance Articles

    1. type links to articles - use PUBMED links to abstracts
    2. add as many as needed
    [edit]

    Pharmacoeconomic Articles

    1. type links to articles - use PUBMED links to abstracts
    2. add as many as needed
    Back to top
    [edit]

    External Links

    Clinical treatment guidelines

    • add clinical treatment guideline external links, if applicable, using bullet points
    • do not link to websites that have a bias to a particular drug, such as manufacturer-sponsored information sites

    Patient information pages

    • add patient information external links, if applicable, using bullet points
    • do not link to websites that have a bias to a particular drug, such as manufacturer-sponsored information sites

    Other resources

    • add other resources using bullet points
    • do not link to websites that have a bias to a particular drug, such as manufacturer-sponsored information sites
    Back to top
    Retrieved from "http://www.smbrower.com/mediawiki/index.php/Olanzapine"
    Personal tools